• About Us
    • Company Overview
    • Our History
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Our Advisors
  • Therapeutic Areas
    • Acute Myocarditis
    • Recurrent Pericarditis
    • Heart Failure
  • Research
    • R&D Partners
    • Our Science
    • Resources
  • Pipeline
  • CardiolRX™
  • Investors
    • Events & Presentations
    • Press Releases
    • Analyst Coverage
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • Contact Us
  • Events & Presentations
  • Press Releases
  • Analyst Coverage
  • Stock Information
  • Filings & Financials
  • Corporate Governance
  • Investor Relations Contact
Investors

Financials

  2022 2021 2020 2019
Financial Statements Q1Q2Q3Q4 Q1Q2Q3Q4 Q1Q2Q3Q4 Q1Q2Q3Q4
MD&A Q1Q2Q3Q4 Q1Q2Q3Q4 Q1Q2Q3Q4 Q1Q2Q3Q4

Regulatory Filings

For a full list of Cardiol Therapeutics’ regulatory filings, please visit SEDAR (Canadian Public Filings) or EDGAR (US Public Filings).

Financial Downloads

Cardiol Therapeutics – 2022 Year End Financial Statements
Cardiol Therapeutics – 2022 Year End MD&A
Cardiol Therapeutics – 2022 Annual Report on Form 20-F
Cardiol Therapeutics – 2021 Year End Financial Statements
Cardiol Therapeutics – 2021 Year End MD&A
Cardiol Therapeutics – 2021 Annual Information Form
Cardiol Therapeutics – 2020 Year End Financial Statements
Cardiol Therapeutics – 2020 Year End MD&A
Cardiol Therapeutics – 2019 Year End Financial Statements
Cardiol Therapeutics – 2019 Year End MD&A
Cardiol Therapeutics – 2018 Year End Financial Statements
Cardiol Therapeutics – 2018 Year End MD&A

 

  • About Us
  • Therapeutic Areas
  • Research
  • Pipeline
  • CardiolRX™
  • Investors
  • Contact

TSX:CRDL NASDAQ:CRDL

Sign up to receive the latest news from Cardiol Therapeutics

© 2023 Cardiol Therapeutics Inc. All rights reserved.      Terms of Use      Privacy Policy